The effects of thrombin on adenylyl cyclase activity were examined in rat adrenal medullary microvascular endothelial Ž . cells RAMEC . Confluent RAMEC monolayers were stimulated for 5 min with cAMP-generating agents in the absence Ž and presence of thrombin, and intracellular cAMP was measured with a radioligand binding assay. Thrombin 0.001-0.25 . Urml dose-dependently inhibited IBMX-, isoproterenol-and forskolin-stimulated cAMP accumulation. A peptide agonist of the thrombin receptor, g-thrombin, and the serine proteases trypsin and plasmin, also inhibited agonist-stimulated cAMP levels, while proteolytically inactive PPACK-or DIP-a-thrombins were without effect. Moreover, the thrombin inhibitor hirudin abolished the inhibitory effect of thrombin but not of the peptide agonist. These results suggest that the inhibitory action of thrombin on cAMP accumulation is mediated by a proteolytically-activated thrombin receptor. The inhibitor of G -proteins pertussis toxin abolished the inhibitory effect of thrombin on isoproterenol-or IBMX-stimulated cAMP i production, while the phorbol ester PMA partly impaired it. The protein kinase C inhibitors staurosporine or H7 and the intracellular Ca 2q chelator BAPTA-AM were without effect. Collectively, our data suggest that the thrombin receptor in RAMEC is negatively coupled to adenylyl cyclase through a pertussis toxin-sensitive G -protein. 
Introduction
Thrombin is a plasma serine protease that induces blood coagulation and also stimulates immediate and long-term responses on various cell types that vary w x depending on the cell type 1,2 . In endothelial cells Ž . EC thrombin increases monolayer permeability, modulates proliferation, induces migration, and in-acid sequence of the new NH -terminus, are able to 2 reproduce many of the vascular actions of thrombin w x 10 . The effects of thrombin are usually short-lived, as the thrombin receptor is rapidly desensitized either due to proteolysis, phosphorylation, or internalization w x 11 .
The hormone-stimulated adenylyl cyclase pathway w x is a well described signaling system 12 . The enzyme adenylyl cyclase is coupled to cell surface receptors Ž . Ž . through both stimulatory G and inhibitory G s i GTP-binding proteins, it catalyzes the formation of Ž . the second messenger cyclic AMP cAMP , and it is expressed in at least 8 distinct isoforms with different w x regulatory properties and tissue distributions 13-17 . Cyclic AMP participates in the regulation of diverse fundamental cellular processes such as proliferation and differentiation, as well as cell type-specific functions. Recently, it has become apparent that, in addition to its second messenger function, cAMP acts as a gate which regulates signal flow through other pathw x ways 18 . The discovery of adenylyl cyclase isoform multiplicity and diversity, together with important new functions ascribed to cAMP, have renewed interw x est in this classical signaling pathway 17, 18 .
The interaction of thrombin with the adenylyl cyclase signaling system has been studied in several cell types. For example, in platelets it was shown that Ž . low -0.1 Urml concentrations of thrombin inhibit cyclic AMP accumulation through activation of a Ž . w x pertussis toxin PTX -sensitive G protein 19,20 . i This observation was later confirmed in fibroblasts w x Ž . 21 , and in human erythroleukemia HEL w x megakaryoblastic cell membranes 22 . However, in intact HEL cells, the same study found that similar doses of thrombin markedly potentiated the cAMP response to prostaglandin and cAMP-increasing w x agents 22 . A stimulatory effect of thrombin on cAMP levels was recently also reported in human w x erythroid progenitor cells 23 . In human umbilical Ž . vein endothelial cells HUVEC , one study found a small but significant increase in cAMP levels followw x ing stimulation with 1 Urml thrombin 24 . Another found a small effect of thrombin on cAMP levels that w x was significantly augmented by cholera toxin 25 , while yet other studies reported that thrombin induces a several-fold increase in cAMP levels in the presw x ence of the phosphodiesterase inhibitor IBMX 3,26 . Based on such evidence, a recent review concluded w x that thrombin increases cAMP levels in EC 11 . In another study, however, no effect of thrombin on intracellular cAMP levels was detected in bovine w x pulmonary artery EC 27 . To date, no inhibitory effects of thrombin on cAMP production have been reported in EC.
In addition to the rather ill-defined role of thrombin in regulating cAMP, EC activation by thrombin involves a number of other well-characterized signaling cascades. Most notably, binding of thrombin to its receptor activates phospholipase C , which in turn b catalyzes the transient production of inositol trisphosphate and diacylglycerol from membrane phosw x phatidylinositols 10 . Inositol trisphosphate mobilizes the release of Ca 2q from internal stores and also contributes to the entry of extracellular Ca 2q , whereas Ž . diacylglycerol activates protein kinase C PKC . Thrombin can also activate phospholipase D, which catalyzes the sustained formation of diacylglycerol from phosphatidylcholine and, thus, the subsequent w x sustained activation of PKC 10 . Interestingly, both PKC and intracellular Ca 2q can affect adenylyl cyw x clase activity through cross-talk interactions 17,28 .
We previously reported the isolation and characterization of a microvascular EC type from the rat w x adrenal medulla, RAMEC 29 . These cells express a w x distinct set of adenylyl cyclase isoforms 30 . Here, we report that thrombin inhibits basal and agoniststimulated cAMP accumulation in RAMEC; this inhibitory action requires proteolytic activation of the thrombin receptor and is sensitive to PTX. These findings suggest that the thrombin receptor in this cell type is negatively coupled to adenylyl cyclase through a G -protein. Further, we present evidence i suggesting that the inhibitory effect of thrombin on cAMP in RAMEC is independent of second messengers generated downstream of the phospholipase C cascade.
Materials and methods

Materials
Human a-and g-thrombins were prepared as prew x viously described 31 . These preparations had fibrinogen clotting activities of 2712 and 10. 
Endothelial cell culture
Microvascular endothelial cells from the rat adrenal Ž . medulla RAMEC were isolated with a modification w x of the method of Mizrachi et al. 33 . Briefly, after removal of the adrenal glands from 5-6 animals, the medullae were excised under a stereo microscope, triturated, and digested with collagenase type I. Pure cultures of endothelial cells were obtained following differential plating and, after establishing colonies of primary isolates, cloning by limited dilution. RAMEC were grown in DMEM medium supplemented with Ž . 10% vrv fetal calf serum, 2 mM L-glutamine, 100 Urml penicillin, 100 mgrml streptomycin, and 5 mgrml fungizone, and passaged with trypsin every 4 days. The endothelial nature of all cultures was routinely confirmed by their hystiotypic, contact-inhibited cobblestone morphology, and by the ability of the cells to endocytose di-indocarbocyamine labelled, acetylated low-density lipoprotein and to express von w x Willebrand factor as previously described 29 . RAMEC from passages 5 to 20, which were used in our experiments, maintain expression of all ECspecific characteristics mentioned above.
Measurement of cAMP
Cells were plated in 12-well plates at a density of 15 000 cells per cm 2 . One day after reaching conflu-Ž . ence 3-4 days after plating , the cells were washed with serum-free medium twice and then stimulated with the various compounds for 5 min in serum-free medium. Physiological activation of the adenylyl cyclase cascade was obtained with the b-adrenergic receptor agonist isoproterenol. In preliminary experiments, we established that maximal stimulation of cAMP accumulation was obtained with 1 mM iso-Ž . proterenol data not shown . Therefore, this concentration of the agonist was used in all subsequent experiments. The diterpene, forskolin, which binds to, and activates adenylyl cyclase with an EC rang-50 w x ing between 5-40 mM 34,35 , was also used, at concentrations of 10 or 100 mM. Further, a lipidsoluble analogue of cAMP, dbcAMP, which is taken up by cells, was used to obtain high intracellular cAMP levels without activation of the upstream signaling cascade. Finally, the phosphodiesterase inhibitor IBMX was used to inhibit cAMP degradation by phosphodiesterases. This is often necessary as the intracellular concentration of cAMP in many cell types, including EC, despite constant production by basally active adenylyl cyclase, is usually kept very low due to continuous degradation of cAMP by w x phosphodiesterases 35 .
At the end of an experiment, cAMP was extracted, and measured by a competitive radioligand binding w x assay, as previously described 35 . The sensitivity of the cAMP assay was 0.25 pmol cAMP per assay tube. The protein content of the wells was determined with a commercially available colorimetric assay kit Ž . Pierce, Rockford, IL according to the manufacturer's instructions. 
Statistical analysis
Each experiment included triplicate wells for each condition tested and was repeated at least 3 times, unless otherwise specified. The results for each experimental group are expressed as mean " S.E.M. The significance of variability amongst various groups was determined by one-way analysis of variance Ž . ANOVA test . Calculations of IC were done with 50 Ž the Origin software package MicroCal Software, . Northampton, MA .
Results
Thrombin modulation of basal and agoniststimulated cAMP accumulation
Incubation of RAMEC for 5 min with isoproterenol, forskolin, IBMX, or dbcAMP, resulted in significantly elevated cAMP levels as compared to un-Ž . stimulated cells Table 1 . When applied to the cells for 1-30 min, and at concentrations of up to 1 Urml, a-thrombin did not significantly affect intracellular Ž . cAMP levels Table 1 and data not shown . When applied immediately before addition of the cAMPelevating compounds, 0.1 Urml of a-thrombin significantly inhibited cAMP accumulation induced by isoproterenol, forskolin, or IBMX, but it did not reduce high intracellular cAMP levels obtained with Ž . dbcAMP Table 1 . Thus, the inhibitory effect of thrombin does not result from its direct effect on the formed cAMP, but occurs at a step of the adenylyl cyclase cascade prior to cAMP formation. Ž The inhibitory effect of thrombin on both basal in . the presence of IBMX as well as isoproterenol-and forskolin-induced cAMP levels was further studied. Significant inhibition of the effect of 1 mM of isoproterenol was found with 0.001 Urml of a-thrombin; this inhibition showed an IC of approx. 0.0015 50 Urml, and reached a maximum level of 85% inhibi- Thrombin was used at 0.1 Urml. Values are mean " S.E.M. of the number of experiments indicated. a Values in this column denote percent inhibition of agonist-stimulated cAMP accumulation in the presence of thrombin, extracted from the raw data presented in the other 2 columns. Basal cAMP levels have been deducted in each case before calculation of the inhibitory effect of thrombin. Two or three asterisks indicate P -0.01 and P -0.001 level of statistical significance, respectively. Fig. 1 . In the cases of forskolin-or IBMX-induced cAMP levels, the threshold concentrations of thrombin required to elicit detectable inhibition were right-shifted by approx. one order of magnitude, while its maximal inhibitory effect on both agents was approx. 50-60% and was Ž . reached also with 0.1 Urml Table 1 , Fig. 1 . The inhibitory effect of higher thrombin concentrations Ž . up to 1 Urml was unchanged in the case of isoproterenol, but it was slightly reduced in the cases of Ž . IBMX and forskolin Fig. 1 and data not shown .
The time requirements for thrombin inhibition were determined by exposing the cells to a-thrombin for 0-15 min, while isoproterenol was added only during the last 5 min of the incubation period. The inhibitory effect was maximal when a-thrombin was applied concomitantly with, or up to 2 min before, addition of the agonist, and gradually declined if thrombin Ž . was applied for longer or shorter periods Fig. 2 . This rapid fall of thrombin's effect is consistent with the previously reported desensitization of the thromw x bin receptor shortly after activation 11 .
To ensure that the reduction of intracellular cAMP levels in thrombin-treated cells was not due to increased extrusion of cAMP from the cell, we measured both the intracellular and medium content of cAMP in cells stimulated with either isoproterenol or forskolin in the presence and absence of thrombin. These experiments showed that the thrombin-induced decrease in agonist-stimulated intracellular cAMP accumulation is not due to increased extrusion of cAMP Ž . in the media data not shown .
Thrombin receptor inÕolÕement
Thrombin activates a G protein-coupled cell surface receptor by proteolytic cleavage and exposure of a new NH -terminus, which in turn binds to and 2 w x activates the receptor 9 . A synthetic thrombin recep-Ž . tor activating peptide TRAP with sequence mimicking this terminus activates the receptor in the absence of thrombin and is able to reproduce many of the w x cellular actions of this protease 9,10 . A concentration of 10 mM of TRAP inhibited isoproterenolinduced cAMP accumulation to a similar extent as Ž . 0.025 Urml of a-thrombin Table 2 . The reduced Ž efficiency of the peptide by more than 3 orders of . magnitude in comparison to thrombin is probably due to the ability of one thrombin molecule to cleave and thus activate many receptor molecules, while each molecule of TRAP can only bind to and activate w x only one receptor molecule 9 . Further, g-thrombin, which lacks the fibrinogen binding site of native w x a-thrombin but retains full proteolytic activity 31 , inhibited isoproterenol-stimulated cAMP accumula-Ž . tion almost as efficiently as a-thrombin Table 2 . By contrast, the proteolytically inactive thrombin w x analogs PPACK-a-thrombin and DIP-a-thrombin 32 had no effect on agonist-induced cAMP accumulation, even when used at concentrations 100 times Ž . higher than a-thrombin Table 2 . Finally, the inhibitor of thrombin activity, hirudin, reduced the inhibitory action of thrombin, but had no effect on Ž . the inhibitory action of TRAP Fig. 3 . These data suggest that the inhibitory action of thrombin on agonist-induced cAMP accumulation is mediated by a proteolytically-activated thrombin receptor.
Inhibition by other proteases
It has been shown that activation of the thrombin receptor following proteolytic cleavage is not a unique property of thrombin but can also be achieved with other serine proteases possessing similar cleavage site w x specificity, such as trypsin and plasmin 9,37 . Both trypsin, a lysinerarginine-specific protease, and plasmin, which has a similar cleavage site specificity as trypsin but with higher specificity for lysine, significantly inhibited isoproterenol-stimulated cAMP accumulation. However, their effect was smaller than that of thrombin even when used at several fold higher Ž . proteolytic activities than thrombin Table 2 . By contrast, elastase, which hydrolyses amides and es-Ž . ters, was without effect Table 2 . These data provide further evidence that proteolytic activation of the thrombin receptor by other serine proteases is sufficient for inhibition of agonist-induced cAMP accumulation, although alternative explanations are possi-Ž . ble see Discussion . . Ž ngrml , did not affect either basal 17.2 " 1.7 and Fig. 3 . Effect of hirudin on the inhibitory action of thrombin or TRAP on isoproterenol-induced cAMP accumulation. RAMEC were preincubated for 10 min with either 0.05 or 0.5 Urml Ž . Ž . hirudin HIR . Thereafter, 0.025 Urml thrombin THR or 2.5 mM TRAP were added, followed by 1 mM isoproterenol. The experiment was terminated 5 min after addition of isoproterenol. Results are expressed as percent of agonist-stimulated cAMP Ž . levels depicted at column C and represent the mean"S.E.M. of triplicate determinations from one representative experiment out Ž ) . of two that gave similar results. Asterisk denotes values Ž . significantly P -0.02 lower than in column C. 18.4 " 1.5 ngrml protein in unstimulated and PTX-. treated cells, n s 3 or isoproterenol-stimulated cAMP Ž . levels Fig. 4b . Similarly, PTX did not alter the IBMX-stimulatory effect on cAMP levels, but it abol-Ž . ished the inhibitory action of thrombin Fig. 4c . These results suggest that thrombin is coupled to adenylyl cyclase through a PTX-sensitive G -protein.
Pertussis toxin sensitiÕity
i Ž In forskolin-stimulated cells, PTX 100 ngrml for . 4 h , not only did not abrogate the inhibitory effect of thrombin on cAMP accumulation, but it had a significant inhibitory effect of its own, similar to the effect Ž . of thrombin Fig. 4d . In the presence of PTX, thrombin was unable to significantly reduce cAMP levels Ž . Fig. 4d . Similar results were obtained with higher Ž . concentrations of PTX up to 1 mgrml . Thus, the presumed direct activation of adenylyl cyclase by w x forskolin 34 may involve a PTX-sensitive step.
Protein kinase C actiÕators and inhibitors
Previous experiments suggested a cross-talk bew x tween PKC and adenylyl cyclase activity 28 . The ability of thrombin to activate PKC in several EC w x types is well documented 6,10 and is also implied Ž . from our results see below, Section 3.7 . To assess the possible involvement of PKC in thrombin-induced inhibition of agonist-stimulated cAMP accumulation, we used the PKC inhibitors H7 and staurosporine, at concentrations considered rather specific Ž for PKC inhibition H7, 10 mM; staurosporine, 100
. w x nM 38 . In 2 independent experiments, each containing 3 wells for each condition tested, preincubation for 30 min with either inhibitor had no effect on either basal, isoproterenol-, or forskolin-stimulated cAMP levels, in the presence or in the absence of Ž . a -thrombin data not shown . It should be noted that both inihibitors were ) 90% effective in inhibiting PKC activity, as determined by using a commercial, Ž non-radioactive PKC assay MESACUP from Medi- cal and Biological Laboratories, Watertown, MA Ž according to the manufacturers' instruction data not . shown . Thus, the involvement of PKC in thrombininduced reduction of cAMP levels in RAMEC. is unlikely.
Ž PKC activation with PMA 1 mM for 5 min or 100 . nM for 10 min did not affect basal cAMP levels Ž 20 " 4.5 and 24.3 " 6.4 pmolrmg protein in unstimulated and PMA-treated cells, respectively, n s . 3 , but it significantly potentiated isoproterenolstimulated cAMP levels when applied concomitantly Ž . with the agonist Fig. 5a . By contrast, forskolin-induced cAM2P production was unaffected by PMA Ž . Fig. 5b . Interestingly, PMA partially reversed the inhibitory effect of thrombin on cAMP levels induced by either of the above agonists. For example, in the case of isoproterenol-induced cAMP accumulation, the inhibitory effect of thrombin was 93 " 5.6% in the absence of PMA, but only 64.6 " 5% in its Ž . presence n s 3, and P -0.05, in both cases . In the case of forskolin-induced cAMP accumulation, the PMA-induced partial reversal of thrombin's effect on forskoln-induced cAMP is apparent from the data shown in Fig. 5b . Collectively, our results with PMA and PKC inhibitors suggest that, while thrombinactivated PKC does not affect cAMP homeostasis, PMA-activated PKC affects both the isoproterenolstimulated cAMP elevation and the thrombin-induced inhibition of this elevation. This apparent dichotomy may reflect differences in the nature of PKC activation by PMA and physiological agonists such as w x thrombin 39 .
Intracellular Ca 2 q chelation
The regulation of adenylyl cyclase activity by 2q w x intracellular Ca has been well documented 17 . To investigate the possibility that thrombin-induced Ca 2q elevation may be involved in the inhibitory effect of this agonist on cAMP accumulation, we used the cell-permeant Ca 2q chelator BAPTA-AM. Incubation of RAMEC with 25 mM BAPTA-AM for 60 min did Ž not affect basal cAMP levels 19.2 " 5 and 16.4 " 4 pmolrmg protein in unstimulated and BAPTA-AM-. treated cells, respectively, n s 3 , but it potently reduced isoproterenol-stimulated cAMP levels both Ž . in the absence and presence of a-thrombin Fig. 6a . The inhibitory effect of thrombin, however, was not Ž affected by intracellular Ca chelation 75.9 " 3.6 and 73.5 " 5% inhibition in the absence and presence . of BAPTA-AM, respectively, n s 3 . Similar results were obtained in forskolin-stimulated cells, although the inhibitory effect of BAPTA-AM was much more Ž . potent in this case Fig. 6b . These results suggest that, while intracellular Ca 2q homeostasis is pivotal for the generation of cAMP by extracellular stimuli, thrombin-induced elevation of intracellular Ca 2q is inconsequential for the inhibitory effect of this protease on agonist-stimulated cAMP accumulation.
Thrombin stimulation of intracellular Ca 2 q
Several studies have shown that thrombin activates phospholipase C and evokes subsequent Ca 2q release Ž from intracellular stores in various types of EC rew x. viewed in 10 . However, no such studies have been reported in RAMEC. We found that monolayers of RAMEC, cultured under identical conditions as in the cAMP measurement studies, responded to thrombin Ž . 0.1-1 Urml with a fast, transient increase in intracellular Ca 2q levels which peaked 15-30 s after addition of the agonist and returned to almost basal Ž . levels within 5 min data not shown . The nature of the thrombin response is characteristic for inositol ( )trisphosphate-induced Ca 2q release from intracellular stores. This result confirms that thrombin activates the phospholipase C cascade also in RAMEC.
Discussion
The major finding of this study is that thrombin inhibits cAMP accumulation in cultured microvascu-Ž . lar EC. This action of thrombin i requires the proteolytic cleavage and activation of the thrombin Ž . receptor, and ii is sensitive to the bacterial toxin PTX. Together, these findings suggest that the thrombin receptor in this cell type is negatively coupled to adenylyl cyclase through a PTX-sensitive G -protein. To the best of our knowledge, our study is the first to demonstrate inhibitory coupling of adenylyl cyclase to the thrombin receptor in endothelial cells. Previous studies found either no effect or increased cAMP w x levels in response to thrombin 3,24-27 . The reasons for the differences between our findings and the previous studies may reside in the types of EC used. Most of the above studies were done in HUVEC or other large vessel EC, while we used cells of microvascular origin. Our preliminary studies with diverse EC types confirm the previously reported stimulatory effect of thrombin on adenylyl cyclase activity in HUVEC, but also suggest that the effect of thrombin on intracellular cAMP levels in different EC types can be inhibitory, stimulatory, or none, depending on the tissue and species origin of the cells Ž Manolopoulos, V.G. and Lelkes, P.I., manuscript in . preparation . This EC type-specific action of thrombin on intracellular cAMP homeostasis further extends our previous findings on the heterogeneity of the adenylyl cyclase signaling system in various types w x of EC 35 .
In an earlier study in fibroblasts, Magnaldo et al. w x 21 found a biphasic effect of thrombin on stimulated adenylyl cyclase consisting of a PTX-sensitive inhibitory effect at concentrations up to 0.1 nM Ž . roughly equivalent to 0.01 Urml , followed by a PKC-mediated potentiating effect at higher concen-Ž . trations 0.1-10 nM . A similar mechanism may account for the partial reduction of the inhibitory effect that we found with higher thrombin concentra-Ž . tions 0.25-1 Urml when forskolin or IBMX were Ž used to activate adenylyl cyclase Fig. 1 and data not   . shown . It should be noted, however, that no such reversal was seen in the case of isoproterenol-Ž activated adenylyl cyclase even at a thrombin dose 1 . Urml equal to the highest dose used in the above Ž . mentioned study data not shown .
The inhibitory effect of thrombin on adenylyl cyw x clase fulfilled several established criteria 9 required for ascribing a cellular action of thrombin to proteolytic activation of the G-protein-coupled thrombin Ž . Ž . receptor Table 2 , Fig. 3 : i TRAP, a synthetic peptide resembling the exposed NH -terminus of the 2 thrombin receptor mimicked the inhibitory action of Ž . thrombin. ii Hirudin, an established thrombin inhibitor, abolished the inhibitory action of thrombin Ž . but not that of TRAP. iii g-Thrombin, which lacks the fibrinogen binding site of a-thrombin but retains full proteolytic activity, was able to reproduce the Ž . inhibitory action of thrombin. iv PPACK-a-thrombin and DIP-a-thrombin, two thrombin analogs lacking proteolytic activity, did not affect agonist-stimulated cAMP levels. Thus, these results leave little doubt that the effect of thrombin on adenylyl cyclase activity is mediated through proteolytic activation of the thrombin receptor.
The efficacy of g-thrombin is somewhat surprising, as the current model of thrombin receptor activation predicts that the anion-binding site of a-throm-Ž . bin which is absent in g-thrombin may be important in positioning the protease on the thrombin receptor for appropriate cleavage of the receptor aminow x terminus 9 . However, this has not been proven to be critical in every case and there are examples in the literature showing that g-thrombin has almost the w x same efficacy as a-thrombin 40-42 . Also, in another study in RAMEC, we found that a-and gthrombins show similar efficacy in stimulating extraw x cellular matrix protein deposition 43 . Moreover, the possibility has not been ruled out that thrombin may proteolytically activate distinct receptors in different speciesrcell types, each of them with different thrombin binding requirements for full activation. w x In agreement with previous reports 9,37 , our results that trypsin and plasmin also reduce agonist-Ž . stimulated cAMP levels Table 2 suggest that proteolytic cleavage of the thrombin receptor after an arginine residue by proteases other than thrombin may be sufficient for its activation. However, the extent of proteolysis of the known thrombin receptor ( )by these proteases was not determined, and it is thus possible that other protease-activated receptors may be involved in the observed effects of trypsin and plasmin. For example, a protease-activated receptor Ž . PAR-2 distinct from the thrombin receptor was recently cloned in the mouse and subsequently found w x also in human EC 44,45 . This receptor is sensitive to trypsin but not to thrombin, thus it is unlikely that the action of thrombin observed in our study is mediated through PAR-2 activation. Nevertheless, the possibility cannot be excluded that the inhibitory effects of trypsin andror plasmin on adenylyl cyclase may be mediated through proteolytic activation of PAR-2 or other protease activated-receptors likely to w x be discovered in the future 46 .
Pertussis toxin ADP-ribosylates and thus inactivates the alpha subunit of the inhibitory G proteins , effectively modulate agonist-stimulated adenylyl cyclase activity in RAMEC. However, the lack of effect of PKC inhibitors and BAPTA-AM argue against a role of phospholipase C signaling in mediating the inhibitory action of thrombin on adenylyl cyclase in this cell type.
Adenylyl cyclase is expressed in at least 8 distinct w x isoforms with different tissue distributions 13,17 . All isoforms are responsive to forskolin and G , but Some clues as to the identity of the isoforms involved in the effects of isoproterenol and thrombin in RAMEC emerge from our results. Firstly, the fact that thrombin activation of a G protein almost comi pletely inhibits the isoproterenol stimulatory effect Ž . suggests that the adenylyl cyclase isoform s activated by isoproterenol are the ones sensitive to G . i a Thus, isoforms I and II can be excluded, as inhibition of isoform I by G is largely absent when the i a G -stimulated activity is examined, while activation s a of G results in activation rather than inhibition of i w x isoform II 14 . In any case, isoform I is an unlikely candidate in EC, as its expression has been shown by w x several studies to be limited to the brain 13,47 . Further, we found that PMA has no significant effect on basal or forskolin-induced cAMP, but it strongly Ž . enhances isoproterenol-induced cAMP levels Fig. 6 . Similar results were recently reported in HT4 neural cells, which express only adenylyl cyclase isoforms I w x and VI 16 . In a previous study, we characterized the expression profile of adenylyl cyclase isoforms in RAMEC: isoforms III and VI are predominant, followed by small amounts of isoform V and only trace amounts w x of isoforms II and IV 30 . Based on these data, we hypothesize that isoform VI -and perhaps also V -may be the principal adenylyl cyclase isoforms mediating the effects of isoproterenol and thrombin on cAMP homeostasis in RAMEC. Additional support for this hypothesis is provided by Taussig et al. w x 15 who showed that G -and forskolin-activated s a isoforms V and VI are strongly inhibited by G .
i a However, it should be noted that in a cell containing many of the known isoforms of adenylyl cyclase, all of which are regulated in a highly complex manner, it is unlikely that a single isoform is solely responsible for the observed effects on cAMP levels. Studies with isoform-specific neutralizing antibodies or antisense oligonucleotides are needed to verify this notion.
Both thrombin and cAMP regulate several functions in EC, and often they do so in an opposing fashion. For example, in HUVEC, thrombin induces tissue factor synthesis and cell surface expression, effects that can be inhibited by elevation of cAMP w x 4 . In the same EC type, thrombin-stimulated platelet activating factor production is inhibited by agents w x that increase cAMP 6 . Also, thrombin is a potent stimulator of EC monolayer permeability, while elevated cAMP not only reduces the permeability of quiescent EC monolayers, but also abolishes the stimw x ulatory action of thrombin 5,8 . Moreover, in a chick chorioallantoic membrane angiogenesis model, w x thrombin stimulates angiogenesis 52 , while cAMPw x elevating agents potently inhibit it 53 . We hypothesize that, through its ability to inhibit adenylyl cyclase, thrombin may provide an endogenous system to antagonize excessive signal transduction by ago-Ž . nists e.g. adrenaline that exert their physiological actions through activation of the adenylyl cyclase pathway. Such a control system may be of special relevance in EC at the adrenal medulla, which represent the first cell layer in the vasculature to be exposed to circulating catecholamines produced by chromaffin cells.
In conclusion, we have shown that thrombin inhibits basal and agonist-stimulated cAMP accumulation in RAMEC; this inhibitory action requires proteolytic activation of the thrombin receptor and is sensitive to PTX. These findings suggest that the thrombin receptor in this cell type is negatively coupled to adenylyl cyclase through a G -protein.
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